Raloxifene prevails in STAR trial, may face easier road to acceptance than previous drugs.
Vastag
Brian
B
D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000517:prevention & control*; D002386:Cataract / Q000139:chemically induced; D000075202:Contraindications; D018849:Controlled Clinical Trials as Topic; D017277:Drug Approval; D020847:Estrogen Receptor Modulators / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D005260:Female; D019584:Hot Flashes / Q000139:chemically induced; D006801:Humans; D010024:Osteoporosis / Q000517:prevention & control; D017698:Postmenopause; D020849:Raloxifene Hydrochloride / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D012307:Risk Factors; D013629:Tamoxifen / Q000627:therapeutic use; D013923:Thromboembolism / Q000139:chemically induced; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration; D014594:Uterine Neoplasms / Q000139:chemically induced
D018931:Antineoplastic Agents, Hormonal; D020847:Estrogen Receptor Modulators; D013629:Tamoxifen; D020849:Raloxifene Hydrochloride